Details of the Drug Combinations

General Information of This Drug (ID: DMI347A)

Drug Name

Lamivudine DMI347A

Synonyms

lamivudine; 134678-17-4; Epivir; Zeffix; Heptovir; Epivir-HBV; Hepitec; Heptodin; BCH-189; 3TC; Heptivir; CIS-LAMIVUDINE; (-)-2'-Deoxy-3'-thiacytidine; 4-amino-1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)pyrimidin-2(1H)-one; GR-109714X; 3'-Thia-2',3'-dideoxycytidine; (-)-BCH-189; Lamivudine [USAN:BAN:INN]; GR109714X; beta-L-3'-Thia-2',3'-dideoxycytidine; beta-L-2',3'-Dideoxy-3'-thiacytidine; (-)NGPB-21; 136891-12-8; 2',3'-Dideoxy-3'-thiacytidine; (-)-BCH 189; UNII-2T8Q726O95; HSDB 7155; GR 109714X; DTHC; LMV; Lamivir; Zefix; BCH 189; BCH189; BCH-790; DRG-0126; Epivir (TN); Epivir(TM); GG-714; HHA & 3TC; HHA & Lamivudine; Heptovir (TN); Lamivudine & GNA; Zeffix (TN); Epivir-HBV (TN); Lamivudine [USAN:INN:BAN]; Lamivudine (JAN/USP/INN); Lamivudine, (2S-cis)-Isomer; Beta-L-2',3'-Dideoxy-3'-thiacytidine; Beta-L-3'-Thia-2',3'-dideoxycytidine; Beta-L-(-)-2',3'-dideoxy-3'-thiacytidine & Sho-Saiko-To; (+/-)-(Cis)-1-[2-(Hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine; (+/-)-3TC; (+/-)-BCH-189; (+/-)-SddC; (-)-(2'R,5'S)-1-[2'-Hydroxymethyl-5'-(1,3-oxathiolanyl)]cytosine; (-)-1-((2R,5S)-2-(Hydroxymethyl)-1,3-oxathiolan-5-yl)cytosine; (-)-1-[(2R,5S)-2-(Hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine; (-)-NGPB-21; (-)-SddC; (-)-beta-L-2',3'-Dideoxy-3'-thiacytidine; (2R,cis)-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one; 2',3' Dideoxy 3' thiacytidine; 2(1H)-Pyrimidinone, 4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl], (+/-)-(Cis); 2(1H)-Pyrimidinone, 4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl], (-)-(2R,5S); 2(1H)-Pyrimidinone, 4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl], (-)-(2R,5S) & Galanthus Nivalis Agglutinin (GNA); 2(1H)-Pyrimidinone, 4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl], (-)-(2R,5S) & Hippeastrum hybrid agglutinin(HHA); 3TC & GNA; 3TC & SST; 3TC (AIDS INITIATIVE) (AIDS INITIATIVE); 3TC and NV-01; 3TC, Zeffix, Heptovir, Epivir, Epivir-HBV, Lamivudine; 4-Amino-1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-2(1H)-pyrimidinone; 4-amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2(1H)-one; 4-amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one; Efavirenz/lamivudine/tenofovir fumarate

Indication

Disease Entry	ICD 11	Status	REF
Chronic HBV infection	1E51.0Z	Approved	[1]
Chronic hepatitis B virus infection	N.A.	Approved	[2]
Human immunodeficiency virus infection	1C62	Approved	[1]
Human immunodeficiency virus-1 infection	1C62	Approved	[3]
Diarrhea	ME05.1	Investigative	[2]
------------------------------------------------------------------------------------

Therapeutic Class

Anti-HIV Agents

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

3 Investigative Drug Combination(s) Consisting of This drug

Normalized Drug Combination Synergy Score

Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Entecavir + Lamivudine	DCQ001S	Entecavir	Hepatitis B virus infection (Cell Line: .)	[4]
Lamivudine + Panobinostat	DCUBZXC	Panobinostat	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[5]
Lamivudine + Idarubicin	DCWYW12	Idarubicin	Glioblastoma? (Cell Line: T98G)	[5]
------------------------------------------------------------------------------------

34 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Dolutegravir + Lamivudine	DC6FEJE	Dolutegravir	HIV	[6]
Dolutegravir + Lamivudine	DC7HBSZ	Dolutegravir	HIV Infections	[7]
Dolutegravir + Lamivudine	DCUEQ7V	Dolutegravir	Human immunodeficiency virus infection	[8]
Dolutegravir + Lamivudine	DCA7NHZ	Dolutegravir	Human immunodeficiency virus infection	[9]
Entecavir + Lamivudine	DCNLS75	Entecavir	Hepatitis B Virus	[10]
Lamivudine + Adefovir	DCA60F9	Adefovir	Chronic Hepatitis B	[11]
Lamivudine + Adefovir	DCJSNX7	Adefovir	Hepatitis B, Chronic	[12]
Lamivudine + Atazanavir	DCLTXS0	Atazanavir	Human Immunodeficiency Virus	[13]
Lamivudine + Tenofovir disoproxil fumarate	DCWVXBK	Tenofovir disoproxil fumarate	Human immunodeficiency virus-1 infection	[9]
Lamivudine + Thymalfasin	DC5MBBH	Thymalfasin	Hepatitis B virus infection	[14]
Lamivudine + Lopinavir	DCGKJVN	Lopinavir	Human immunodeficiency virus-1 infection	[15]
Stavudine + Lamivudine	DCHL064	Stavudine	HIV Infections	[16]
Tenofovir disoproxil + Lamivudine	DC10B31	Tenofovir disoproxil	Lymphoma	[17]
Zidovudine + Lamivudine	DCH0XO7	Zidovudine	HIV	[18]
Dolutegravir + Lamivudine	DCK6V4R	Dolutegravir	HIV-1 Infection	[19]
Dolutegravir + Lamivudine	DCAF4N7	Dolutegravir	HIV-1 Infection	[20]
Entecavir + Lamivudine	DCBH8D1	Entecavir	Non-Hodgkin Lymphoma	[21]
Nevirapine + Lamivudine	DCT6FBL	Nevirapine	HIV Infections	[22]
Tenofovir + Lamivudine	DCMJWN4	Tenofovir	HIV Infections	[23]
Zidovudine + Lamivudine	DCGON3K	Zidovudine	HIV Infections	[24]
Aspirin + Lamivudine	DCKZ7JM	Aspirin	Hepatocellular Carcinoma	[25]
Dolutegravir + Lamivudine	DC7UAKK	Dolutegravir	Infection, Human Immunodeficiency Virus	[26]
Lamivudine + Atazanavir	DCHS312	Atazanavir	HIV	[27]
Lamivudine + Raltegravir	DCL834N	Raltegravir	HIV Infections	[28]
Tenofovir + Lamivudine	DCBEIYG	Tenofovir	Human Immunodeficiency Virus	[29]
Tenofovir + Lamivudine	DCEBNVB	Tenofovir	HIV Infections	[30]
Zidovudine + Lamivudine	DCPC7VB	Zidovudine	Human Immunodeficiency Virus	[29]
Zidovudine + Lamivudine	DC4OLI4	Zidovudine	Malaria	[31]
Zidovudine + Lamivudine	DCZJZHV	Zidovudine	HIV Infections	[32]
Dolutegravir + Lamivudine	DCBJPXX	Dolutegravir	HIV-1-infection	[33]
Lamivudine + Darunavir	DC7TBXK	Darunavir	Patient Compliance	[34]
Lamivudine + Raltegravir	DCJC0HZ	Raltegravir	Hiv	[35]
Sorbitol + Lamivudine	DCCG3DH	Sorbitol	Infection, Human Immunodeficiency Virus	[36]
Stavudine + Lamivudine	DCJHKTX	Stavudine	HIV	[37]
------------------------------------------------------------------------------------


⏷ Show the Full List of 34 DrugCom(s)

References

1	Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
2	Lamivudine FDA Label
3	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
4	The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
5	Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
6	ClinicalTrials.gov (NCT02384395) Safety and Efficacy of Fixed Dose Combination Dolutegravir/Abacavir/Lamivudine FDC Initiated During Acute HIV Infection
7	ClinicalTrials.gov (NCT04019873) 'COMBINE-2': Real-world Evidence for Effectiveness of Two Drug Regimen, Antiretroviral Therapy With Integrase Inhibitors Plus a Reverse Transcriptase Inhibitor
8	Abacavir/dolutegravir/lamivudine single-tablet regimen: a review of its use in HIV-1 infection. Drugs. 2015 Apr;75(5):503-14.
9	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
10	ClinicalTrials.gov (NCT01438424) Safety and Antiviral Activity of Entecavir in Participants With Chronic Hepatitis B Following Monotherapy in Other Entecavir Trials
11	ClinicalTrials.gov (NCT00798460) Efficacy of Clevudine Plus Lamivudine for Lamivudine-resistant Chronic Hepatitis B Patients
12	ClinicalTrials.gov (NCT00410202) Entecavir Plus Adefovir Combination Therapy Versus Entecavir Monotherapy vs Therapy With Adefovir Plus Lamivudine for Chronic Hepatitis B Infected Subjects With Lamivudine-resistant Virus
13	ClinicalTrials.gov (NCT02652793) Simplification From Tenofovir Plus Lamivudine or Emtricitabine Plus Ritonavir-Boosted-Protease Inhibitor to Ritonavir-Boosted-Atazanavir Plus Lamivudine in Virologically-Suppressed-HIVInfected Adults With Osteopenia
14	Clinical pipeline report, company report or official report of SciClone.
15	ClinicalTrials.gov (NCT00043953) Lopinavir/Ritonavir in Combination With Saquinavir Mesylate or Lamivudine/Zidovudine to Explore Metabolic Toxicities in Antiretroviral HIV-Infected Subjects. U.S. National Institutes of Health.
16	ClinicalTrials.gov (NCT00004578) ABT-378/Ritonavir in Combination With Reverse Transcriptase Inhibitors in Antiretroviral Nave HIV-Infected Subjects
17	ClinicalTrials.gov (NCT01528865) Safety & Efficacy of Lamivudine & Tenofovir to Lower Plasma Level of Viral RNA in Lymphoma
18	ClinicalTrials.gov (NCT00960622) Switch From Combivir or Trizivir to Truvada - Mitochondrial Effects
19	ClinicalTrials.gov (NCT02566707) Pharmacokinetics of Atazanavir /Dolutegravir/Lamivudine Regimen as Maintenance Regimen
20	ClinicalTrials.gov (NCT02582684) Dolutegravir Plus Lamivudine Dual Therapy in Treatment Nave HIV-1 Patients
21	ClinicalTrials.gov (NCT01914744) Entecavir Versus Lamivudine for Preventing the Risk of Hepatitis B Reactivation in NHL
22	ClinicalTrials.gov (NCT02116660) Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
23	ClinicalTrials.gov (NCT00100048) A Study to Evaluate the Safety and Efficacy of an Investigational Drug in HIV Infected Patients (0518-004)(COMPLETED)
24	ClinicalTrials.gov (NCT00307151) Antiviral Responses to NNRTI-Based vs. PI-Based ARV Therapy in HIV Infected Infants Who Have or Have Not Received Single Dose NVP for Prevention of Mother-to-Child Transmission of HIV
25	ClinicalTrials.gov (NCT01936233) Clinical Study of Antiviral and Aspirin Treatment in Liver Cancer After Radical Surgery
26	ClinicalTrials.gov (NCT02831673) An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment nave HIV Infected Subjects (Gemini 1)
27	ClinicalTrials.gov (NCT01620944) Open-Label Study Comparing Efficacy and Safety of ATV/RTV+3TC With ATV/RTV+TDF/FTC in HIV-Infected, Treatment Nave Subjects, Followed by Treatment With ATV/RTV+3TC
28	ClinicalTrials.gov (NCT03311945) Simplification Study of HIV-1 Infected Patients With Virological Suppression Under the Combination of Lamivudine (150 mg BID) Plus Raltegravir (400 mg BID) Switching to Lamivudine (300 mg QD) Plus Raltegravir (1200 mg QD) : Roll-over Study of the RALAM
29	ClinicalTrials.gov (NCT03988452) Nucleosides And Darunavir/Dolutegravir In Africa
30	ClinicalTrials.gov (NCT02369965) Test Albuvirtide in Experienced Patients. U.S. National Institutes of Health.
31	ClinicalTrials.gov (NCT00993031) Protease Inhibitors to Reduce Malaria Morbidity in HIV-Infected Pregnant Women
32	ClinicalTrials.gov (NCT02181933) Efficacy of Nevirapine Compared to ZDV + 3TC Administered in Labor and Again at Postdelivery in HIV Positive Women
33	ClinicalTrials.gov (NCT03360682) Clinical Trial to Evaluate the Efficacy, Pharmacokinetics (PK) Interactions and Safety of Dolutegravir Plus 2 Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in HIV-1-Infected Solid Organ Transplant Patients
34	ClinicalTrials.gov (NCT02470650) Cost-effectiveness of Different Antiretroviral Treatment in Patients HIV Naive
35	ClinicalTrials.gov (NCT03205566) Time to Protection and Adherence Requirements of Raltegravir With or Without Lamivudine in Protection From HIV Infection
36	ClinicalTrials.gov (NCT02634073) A Phase IV, Open Label, 4-period Cross-over Study to Investigate a Drug Interaction Between Lamivudine and Sorbitol Oral Solutions in Healthy Volunteers
37	ClinicalTrials.gov (NCT00342355) Antiretroviral Therapy for Advanced HIV Disease in South Africa